8886 RESULTS
COMMENT Findings associating the pathology of Alzheimer disease (AD) with inflammatory cells led to epidemiological and clinical investigations showing that broad-based anti-inflammatories reduce the incidence of AD. Mirzoeva et al. describe a new ...
COMMENT I don't think this paper definitively rules IDE out as a LOAD gene. It simply says the authors could not find evidence for it in a case-control study of about 150 subjects with LOAD. It is not uncommon for different genetic methods to not confirm ...
COMMENT Our new compounds appear to have a different mechanism of action from currently available inhibitors that target COX-2 or p38 MAPK pathways, suggesting that additional signal transduction pathways exist that can be targeted for glial activation and ...
COMMENT Author Comment Background: Increasing research efforts are directed at detecting Alzheimer's in its earliest stages, including those before it is clinically symptomatic. Understanding the brain changes that occur early in the disease will be key to ...
COMMENT The main finding that cholinergic deficits were not evident in early to mid-stage Alzheimer's disease challenges the rationale for current Alzheimer's therapy, which has been the premise that cholinergic deficits exist early in the illness and ...
COMMENT The authors bring up some interesting points and I concur that sex steroid hormones probably play a role, whether directly or indirectly, in the pathogenesis of AD. However, the authors' conclusions fail to consider at least two confounding factors. ...
COMMENT This research group uses hyperthermia to induce a form of generalized stress that this group calls "heat shock" in its reports, but it is my understanding that this group is alone in application of this nomenclature. Exposure of cultured cells ...
COMMENT In developing small molecule therapeutics, drug hunters targeting neurodegenerative diseases have to overcome an added barrier, both figuratively and literally. In general, the experimental therapeutic must pass the blood-brain-barrier (BBB) in order to ...
COMMENT I have read with interest the comment on HFE mutations and AD. Our group also postulated that a genetic defect in iron metabolism could be associated with a greater risk for AD. Therefore, we analyzed the two common HFE mutations and the Transferrin C2 ...
COMMENT The observation that, in vitro, urocortin provides neuroprotection to vulnerable neurons may have some therapeutic implications in Alzheimer's disease (AD). However, these implications are not clear-cut, since other studies have shown that ...
COMMENT Author's Response We read with interest the comments of Mark Smith and George Perry, which raise interesting philosophical points but do not directly address the results in our recent paper. In our peer-reviewed report, we describe a new class of ...
COMMENT Three principal issues arise from the literature reviewed by Dr. Wolozin and his comments: (1) an evolving concept that previously separated forms of parkinsonism actually present heterogeneity of one and the same Parkinson's disease (PD) syndrome; ...
COMMENT As indicated in our paper (Shoghi-Jadid et al, 2002), we agree with Dr. Klunk's point that additional study of our new amyloid-binding agent is needed. Clearly, no single publication could have addressed all the additional areas that need to be ...
COMMENT Sperling and colleagues demonstrate how functional brain imaging, behavioral analyses, and pharmacological manipulations can be integrated within an interdisciplinary study of the pharmacology of memory and memory impairments. Their important contribution ...
COMMENT Shoghi-Jadid and colleagues at UCLA are to be congratulated for their publication in Am. J. Geriatric Psychiatry, which represents the first full publication of an attempt to image amyloid and neurofibrillary tangle (NFT) deposition with PET in Alzheimer& ...
